191 related articles for article (PubMed ID: 7586904)
1. Ondansetron clinical pharmacokinetics.
Roila F; Del Favero A
Clin Pharmacokinet; 1995 Aug; 29(2):95-109. PubMed ID: 7586904
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron metabolism and pharmacokinetics.
Pritchard JF
Semin Oncol; 1992 Aug; 19(4 Suppl 10):9-15. PubMed ID: 1387254
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron: a novel antiemetic agent.
Figg WD; Graham CL; Hak LJ; Dukes GE
South Med J; 1993 May; 86(5):497-502. PubMed ID: 8488393
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Baber N; Palmer JL; Frazer NM; Pritchard JF
Eur J Anaesthesiol Suppl; 1992 Nov; 6():11-8. PubMed ID: 1425620
[TBL] [Abstract][Full Text] [Related]
5. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ondansetron in patients with hepatic insufficiency.
Figg WD; Dukes GE; Pritchard JF; Hermann DJ; Lesesne HR; Carson SW; Songer SS; Powell JR; Hak LJ
J Clin Pharmacol; 1996 Mar; 36(3):206-15. PubMed ID: 8690814
[TBL] [Abstract][Full Text] [Related]
7. [Ondansetron: a specific 5-HT3 serotonin receptor inhibitor, a new antiemetic in oncology].
d'Allens H; Aubert B; Bons J; Pappo M
Bull Cancer; 1991; 78(12):1139-46. PubMed ID: 1838490
[TBL] [Abstract][Full Text] [Related]
8. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
Kaiser R; Sezer O; Papies A; Bauer S; Schelenz C; Tremblay PB; Possinger K; Roots I; Brockmöller J
J Clin Oncol; 2002 Jun; 20(12):2805-11. PubMed ID: 12065557
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron absorption in adults: effect of dosage form, food, and antacids.
Bozigian HP; Pritchard JF; Gooding AE; Pakes GE
J Pharm Sci; 1994 Jul; 83(7):1011-3. PubMed ID: 7965657
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of ondansetron. A review.
Simpson KH; Hicks FM
J Pharm Pharmacol; 1996 Aug; 48(8):774-81. PubMed ID: 8887724
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery.
Spahr-Schopfer IA; Lerman J; Sikich N; Palmer J; Jorch U
Clin Pharmacol Ther; 1995 Sep; 58(3):316-21. PubMed ID: 7554705
[TBL] [Abstract][Full Text] [Related]
12. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Jun; 26(7):1001-8. PubMed ID: 10396331
[TBL] [Abstract][Full Text] [Related]
14. A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron.
Cox EH; Veyrat-Follet C; Beal SL; Fuseau E; Kenkare S; Sheiner LB
J Pharmacokinet Biopharm; 1999 Dec; 27(6):625-44. PubMed ID: 11153449
[TBL] [Abstract][Full Text] [Related]
15. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum.
Hsyu PH; Pritchard JF; Bozigian HP; Lloyd TL; Griffin RH; Shamburek R; Krishna G; Barr WH
Pharm Res; 1994 Jan; 11(1):156-9. PubMed ID: 8140047
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
18. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
19. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
